CAR-T therapy with glofitamab for relapsed B-cell lymphoma
Part of Cancer clinical trials.
This trial tests a new approach to treating aggressive B-cell lymphomas that have returned or didn't respond to initial chemotherapy. It combines a drug called glofitamab with CAR-T cell therapy (immune cells engineered in the lab to fight cancer) to see if it improves outcomes for patients who are candidates for this advanced treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Diagnosed with large B-cell lymphoma that came back or didn't respond to first-line chemotherapy
- Received initial chemotherapy containing R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone)
- Age 18–80 years old with good overall health status (ECOG performance status 0–2)
- Have measurable tumors on PET scan or CT scan
- Healthy kidney, liver, heart, and bone marrow function; able to undergo CAR-T cell collection
- Not pregnant or breast-feeding; willing to use contraception if of childbearing age
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study is testing a new combination of two treatments—glofitamab (a targeted antibody) and CAR-T cell therapy—for people with relapsed or refractory large B-cell lymphoma. It is for patients who have not responded to or have relapsed after at least one prior treatment and have certain high-risk features.
This trial tests a new combination approach for people whose aggressive B-cell lymphoma has come back or not responded to treatment. It uses a bispecific antibody (a type of drug that helps immune cells attack cancer cells) followed by CAR-T cell therapy (reprogramming your own immune cells to find and kill cancer), sometimes with a stem cell transplant.
This trial tests two immune-based treatments—first a special type of immunotherapy (CAR T-cells, called axi-cel), then a targeted antibody drug (glofitamab)—for people with large B-cell lymphoma that did not fully respond to their first treatment or came back within a year. The goal is to see if this combination can help more people achieve lasting remission.
This trial tests combining two therapies—a CAR T-cell treatment and an antibody drug called glofitamab—for people with large B-cell lymphoma that has come back or not responded to initial treatment and has certain high-risk features.
This trial tests a combination of two treatments: a CAR-T cell therapy (relmacabtagene autoleucel) and an immunotherapy drug (sintilimab) for people with certain types of B-cell lymphoma that have come back or stopped responding to other treatments. The goal is to see if this combination can help control the cancer.
This trial tests a special cell therapy called CAR-T that targets CD19 on lymphoma cells. It is for people with aggressive large B-cell lymphoma that has not responded to standard treatments or has come back after treatment.
Hear when a new Relapsed /Refractory DLBCL trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.